# Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

> **NCT06524739** · PHASE3 · TERMINATED · sponsor: **CSL Behring** · enrollment: 16 (actual)

## Conditions studied

- Post-COVID Postural Orthostatic Tachycardia Syndrome

## Interventions

- **BIOLOGICAL:** IgPro20
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06524739
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-08-28
- **Primary completion:** 2025-06-20
- **Final completion:** 2025-07-11
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Sponsor decision, not for safety reasons.
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06524739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06524739, "Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT06524739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*